1Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada[J]. Semin Arthritis Rheum, 2008. [Epub ahead of print] PubMed PMID: 18706680.
3Sunderkotter C, Herrgott I, Brtickner C, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors[J]. Br J Dermatol, 2009, 160(4): 835-843.
3Masi AT, Rodnan GP, Medesger TA. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee [J]. Arthritis Rheum, 1980, 23(5): 581-590.
4Steen VD, Medsger TA Jr, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis[J]. Ann Intern Med, 1982, 97(5): 652-659.
5Jacobsen S, Halberg P, Ullman S. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis[J]. Br J Rheumatol, 1998, 37(1): 39-45.
6Ihn H, Yamane K, Yazawa N. Distribution and antigen specificity of anti - U1RNP antibodics in patients with systcmic sclcrosis [J]. Clin Exp Immunol, 1999, 117(2): 383-387.
7Okano Y, Steen VD, Medsger TA. Autoantibody to U3 nuclerolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis[J].Arthritis Rheum, 1992, 35(1): 95-100.
8Jacobsen S, Ullman S, Shen GQ. Influence of clinical features,serum antinuclear antibodies, and lung function on survival of patients with sclerosis[J]. J Rheumatol, 2001, 28(11): 2454-2459.
